Prostatic adenocarcinoma following androgen deprivation therapy: the new difficulty in histologic interpretation.
Bostwick
D G
DG
Department of Pathology, Mayo Clinic, Rochester, Minnesota, USA.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D000726:Androgen Antagonists / Q000627:therapeutic use*; D042944:Cholestenone 5 alpha-Reductase; D003937:Diagnosis, Differential; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D018120:Finasteride / Q000627:therapeutic use; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D010088:Oxidoreductases / Q000037:antagonists & inhibitors; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*
D000726:Androgen Antagonists; D004791:Enzyme Inhibitors; D018120:Finasteride; D010088:Oxidoreductases; D042944:Cholestenone 5 alpha-Reductase